131987-16-1

Basic information

• Product Name: 3-(3-butylthio-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine
• Synonyms: 3-(3-butylthio-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine
• CAS NO: 131987-16-1
• Molecular Formula: C12H19 N3 S2
• Molecular Weight: 0
• Mol File: 131987-16-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 380.8°Cat760mmHg
• Flash Point: 184.1°C
• Appearance: /
• Density: 1.2g/cm³
• Vapor Pressure: 5.33E-06mmHg at 25°C
• Refractive Index: 1.595
• CAS DataBase Reference: 3-(3-butylthio-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3-butylthio-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine(131987-16-1)
• EPA Substance Registry System: 3-(3-butylthio-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine(131987-16-1)

Safety Data

• Hazardous Substances Data: 131987-16-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H19N3S2/c1-3-4-8-16-12-11(13-17-14-12)10-6-5-7-15(2)9-10/h6H,3-5,7-9H2,1-2H3

Upstream product

• 500-22-1 3-pyridinecarboxaldehyde 
• 131986-28-2 3-(4-chloro-1,2,5-thiadiazol-3-yl)pyridine 
• 131988-63-1 2-amino-2-(pyridin-3-yl)acetonitrile 
• 131987-99-0 3-(3-butylthio-1,2,5-thiadiazol-4-yl)pyridine 
• 74-88-4 methyl iodide 
• 131988-52-8 3-(3-butylthio-1,2,5-thiadiazol-4-yl)-1-methylpyridinium iodide 

Relevant articles and documents

Muscarinic agonists with antipsychotic-like activity: Structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity

Muscarinic agonists were tested in two models indicative of clinical antipsychotic activity: conditioned avoidance responding (CAR) in rats and inhibition of apomorphine-induced climbing in mice. The standard muscarinic agonists oxotremorine and pilocarpine were both active in these tests but showed little separation between efficacy and cholinergic side effects. Structure-activity relationships of the alkylthio-1,2,5-thiadiazole azacyclic type muscarinic partial agonists are shown, revealing the exo-6-(3- propyl/butylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane analogues (4a,b and 9a,b) to be the most potent antipsychotic agents with large separation between efficacy and cholinergic side effects. The lack of enantiomeric selectivity suggests the pharmacophoric elements are in the mirror plane of the compounds. A model explaining the potency differences of closely related compounds is offered. The data suggest that muscarinic agonists act as functional dopamine antagonists and that they could become a novel treatment of psychotic patients.

Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives

The present invention relates to a novel method for treating a mammal suffering from urinary bladder dysfunctions.